A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
← catalyst calendarNCT06388564 · readout in 286 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
130actual
Sites
68
Countries
Belgium, Canada, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-11 | actual | When the study began enrolling |
| Primary completion | 2027-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Graft-versus-host-disease
Interventions
- Drug: Axatilimab
- Drug: Ruxolitinib
- Drug: Corticosteroids — also filed as prednisone, prednisolone, methylprednisolone
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate
measured 6 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed